

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
08 October 2020 (08.10.2020)



(10) International Publication Number  
**WO 2020/206115 A3**

(51) International Patent Classification:  
C12N 15/113 (2010.01) C07K 14/515 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:  
PCT/US2020/026379

**Declarations under Rule 4.17:**

— of inventorship (Rule 4.17(iv))

(22) International Filing Date:  
02 April 2020 (02.04.2020)

**Published:**

— with international search report (Art. 21(3))  
— before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments (Rule 48.2(h))  
— with sequence listing part of description (Rule 5.2(a))

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
62/828,864 03 April 2019 (03.04.2019) US

(88) Date of publication of the international search report:  
12 November 2020 (12.11.2020)

(71) Applicants: **BRISTOL-MYERS SQUIBB COMPANY**  
[US/US]; Rt. 206 & Province Line Road, Princeton, New  
Jersey 08543 (US). **ROCHE INNOVATION CENTER**  
**COPENHAGEN A/S** [—/DK]; Fremtidsvej 3, DK2970  
Horsholm (DK).

(72) Inventors: **ANDERSON, Brian R.**; Rt. 206 & Province  
Line Road, Princeton, New Jersey 08543 (US). **OLSON,**  
**Richard E.**; Rt. 206 & Province Line Road, Princeton, New  
Jersey 08543 (US). **MCDONALD, Ivar M.**; Rt. 206 &  
Province Line Road, Princeton, New Jersey 08543 (US).  
**MERCER, Stephen E.**; Rt. 206 & Province Line Road,  
Princeton, New Jersey 08543 (US). **HAGEDORN, Peter**;  
Fremtidsvej 3, DK2970 Horsholm (DK). **JENSEN, Mari-**  
**anne Lerbech**; Torsvej 7, 4600 Koge (DK).

(74) Agent: **KIM, Ji Eun** et al.; Sterne, Kessler, Goldstein &  
Fox, 1100 New York Avenue, NW, Washington, District of  
Columbia 20005 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,  
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,  
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,  
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,  
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,  
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: ANGPTL2 ANTISENSE OLIGONUCLEOTIDES AND USES THEREOF

(57) Abstract: The present disclosure relates to antisense oligonucleotides, which target ANGPTL2 mRNA in a cell, leading to reduced expression of ANGPTL2 protein. Reduction of ANGPTL2 protein expression is beneficial for the treatment of certain medical disorders, such as those associated with abnormal ANGPTL2 expression and/or activity e.g., cardiovascular-related diseases or disorders.



WO 2020/206115 A3